Subsequently, the phase 3 EMBRACA trial with 431 BRCA1/2-mutated advanced breast cancer patients, talazoparib monotherapy exhibits significant PFS benefit when compared with standard chemotherapy, with the talazoparib group objective responsive rate significantly higher than the standard chemotherapy group (62.6% vs. 27.2%, respectively; P < 0.001) [104]. Here, BRCA1 is linked to breast cancer.